| Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol | PMID 36878237无 PMCID | 2023-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.Lung | PMID 36879087PMC10115701 | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of a transdermal donepezil patch in patients with mild-to-moderate Alzheimer's disease: A 24-week, randomized, multicenter, double-blind, parallel group, non-inferiority study.Geriatr Gerontol Int | PMID 36894171无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.Gynecol Oncol | PMID 36898292PMC10286827 | 2023-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| VV116 as a potential treatment for COVID-19.Expert Opin Pharmacother | PMID 36932818无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.CNS Drugs | PMID 36947322PMC10126024 | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial.Cephalalgia | PMID 36950929无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.Lancet Oncol | PMID 36990608无 PMCID | 2023-Apr | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE.Lupus Sci Med | PMID 37012059PMC10083883 | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.Nat Med | PMID 37069359PMC10115633 | 2023-Apr | 0.95 | The study is a randomized phase 3 trial in oncology with a drug intervention and reports primary efficacy results. However, it is excluded because its primary and secondary endpoints are cytometric outcomes (stem cell collection success), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). | 待处理 |
| Efficacy and safety of Diclofenac sodium plaster in patients with acute pain of the limbs: a randomized, placebo and active-controlled, double-blind, parallel-group trial.Eur Rev Med Pharmacol Sci | PMID 37070921无 PMCID | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).JCO Clin Cancer Inform | PMID 37084329PMC10281446 | 2023-Apr | 0.50 | While the record describes a Phase III randomized oncology trial (S1400I), the abstract focuses exclusively on adverse event visualization methodology. It does not report any survival, progression, recurrence, death, hazard, time-to-event, or other efficacy outcomes, which are required for inclusion in the Kaplan-Meier digitization cohort. | 待处理 |
| Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study.RMD Open | PMID 37094983PMC10124319 | 2023-Apr | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.Future Oncol | PMID 37222151无 PMCID | 2023-Apr | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.Nephrol Dial Transplant | PMID 35751625PMC10064978 | 2023-Mar-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).Lancet | PMID 36848918无 PMCID | 2023-Mar-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).Lancet | PMID 36848919无 PMCID | 2023-Mar-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.Vaccine | PMID 36828719无 PMCID | 2023-Mar-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.Vaccine | PMID 36868877PMC9915113 | 2023-Mar-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.N Engl J Med | PMID 36920778无 PMCID | 2023-Mar-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination.Sci Rep | PMID 36944716PMC10028771 | 2023-Mar-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.J Clin Oncol | PMID 36669146PMC10022862 | 2023-Mar-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.Lancet | PMID 36842439无 PMCID | 2023-Mar-18 | 0.90 | The study is a Phase III randomized controlled trial for nasopharyngeal carcinoma with overall survival as a primary time-to-event endpoint. However, the intervention compares two radiotherapy fractionation schedules (hyperfractionated vs. standard fractionated intensity-modulated radiotherapy), which is a non-drug-only intervention. Drug intervention is not present or established. | 待处理 |
| Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study).Oncologist | PMID 36426809PMC10020805 | 2023-Mar-17 | 0.95 | This is a randomized Phase III trial in human oncology patients, but the primary outcome (proportion of subjects requiring high-dose opioids based on genotype) is not a survival, progression, recurrence, death, hazard, or time-to-event efficacy outcome as required for Kaplan-Meier digitization. | 待处理 |
| Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.Signal Transduct Target Ther | PMID 36928584PMC10020443 | 2023-Mar-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy.BMC Neurol | PMID 36932361PMC10022100 | 2023-Mar-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.N Engl J Med | PMID 36762851无 PMCID | 2023-Mar-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19.Crit Care | PMID 36927455PMC10018638 | 2023-Mar-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized, Multicenter, Phase 3 Study of Accelerated Fraction Radiation Therapy With Concomitant Boost to the Gross Tumor Volume Compared With Conventional Fractionation in Concurrent Chemoradiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer: The Korean Radiation Oncology Group 09-03 Trial.Int J Radiat Oncol Biol Phys | PMID 36280151无 PMCID | 2023-Mar-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.Schizophr Bull | PMID 36305696PMC10016392 | 2023-Mar-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia.Neurology | PMID 36517235PMC10074464 | 2023-Mar-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.Lancet | PMID 36774933PMC10259621 | 2023-Mar-11 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.J Clin Oncol | PMID 36413710PMC10022857 | 2023-Mar-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial.J Clin Oncol | PMID 36599114PMC10022849 | 2023-Mar-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.Vaccine | PMID 36781334PMC9910015 | 2023-Mar-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.N Engl J Med | PMID 36884323PMC11225596 | 2023-Mar-09 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Roussel M, Lauwers-Cances V, Macro M, et al. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood. 2022;139(18):2747-2757.Blood | PMID 36893003无 PMCID | 2023-Mar-09 | 0.45 | Metadata indicates an oncology randomized phase 3 trial, but lacks abstract or keywords to confirm human subjects and specific survival/progression outcomes. Insufficient to establish eligibility without further review. | 待处理 |
| Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.Lancet | PMID 36746171无 PMCID | 2023-Mar-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.Lancet | PMID 36764316无 PMCID | 2023-Mar-04 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Assessment of Autologous Blood marker localIzation and intraoperative coLonoscopy localIzation in laparoscopic colorecTal cancer surgery (ABILITY): a randomized controlled trial.BMC Cancer | PMID 36869328PMC9985272 | 2023-Mar-03 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study.Mod Rheumatol | PMID 35482532无 PMCID | 2023-Mar-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.Blood | PMID 36399712PMC10163280 | 2023-Mar-02 | 0.90 | The trial is a randomized, placebo-controlled phase 3 study of a drug (leniolisib) in human oncology (APDS with lymphoma risk), but it does not report a time-to-event efficacy endpoint such as overall survival, progression-free survival, or any other time-to-event outcome with Kaplan-Meier or hazard ratio. The primary endpoints are changes in lymph node size and immune cell subsets. Therefore, it does not meet the inclusion criterion for a time-to-event efficacy endpoint. | 待处理 |
| Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.N Engl J Med | PMID 36856616无 PMCID | 2023-Mar-02 | 0.95 | The study is a Phase III randomized controlled trial in an oncology population (skin cancer chemoprevention) with a drug intervention, but the primary endpoint is the number of new keratinocyte cancers during the intervention period (a count/rate outcome), not a time-to-event endpoint (e.g., OS, PFS, DFS, TTP) with Kaplan-Meier analysis or hazard ratios. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint for Kaplan-Meier digitization. | 待处理 |
| Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III).J Atheroscler Thromb | PMID 35599000PMC9981351 | 2023-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD).J Clin Oncol | PMID 36409969无 PMCID | 2023-Mar-01 | 0.95 | The study is a Phase III randomized, placebo-controlled trial in advanced cancer patients with a drug intervention (cannabidiol oil). However, the primary endpoint (ESAS total symptom distress score at day 14) and key secondary endpoints are not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) and do not report Kaplan-Meier estimates or hazard ratios for such endpoints. The study evaluates symptom relief and quality of life in palliative care, not a direct efficacy endpoint for tumor response or survival. | 待处理 |
| Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.J Clin Oncol | PMID 36455168PMC9995104 | 2023-Mar-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial.JAMA Cardiol | PMID 36652223PMC9857843 | 2023-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.JAMA Neurol | PMID 36689214PMC9871944 | 2023-Mar-01 | 0.90 | This is a Phase 3 randomized controlled trial of a biosimilar natalizumab for relapsing-remitting multiple sclerosis (non-oncology). The primary efficacy endpoint is an imaging endpoint (cumulative number of new active lesions on MRI), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). | 待处理 |
| Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.Am J Psychiatry | PMID 36789515无 PMCID | 2023-Mar-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.Diabetes Obes Metab | PMID 36478142PMC10107759 | 2023-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |